REGENXBIO Hosts Investor Event on Sura-Vec for Wet AMD

ROCKVILLE, Md., Oct. 12, 2026 /CourierPR/ -- REGENXBIO Inc., a biotechnology company focused on gene therapy, is set to host an investor event on Tuesday, October 20, 2026, at 1:00 p.m. ET. The event will be held in New York, NY, and will also be available via webcast. The primary focus of the event is to review the clinical program of surabgene lomparvovec (sura-vec, ABBV-RGX-314) in the treatment of wet age-related macular degeneration (wet AMD). This comes ahead of the anticipated topline pivotal data readout in the fourth quarter of 2026.

The event will feature a comprehensive overview of the sura-vec clinical program and insights from leading retina specialists. Key opinion leaders, including Dr. Gaurav Shah from California Pacific Medical Center, Sutter Health; Dr. Arshad Khanani from Sierra Eye Associates; Dr. Lejla Vajzovic from Duke University School of Medicine; Dr. Rahul Khurana from Northern California Retina Vitreous Associates, University of California at San Francisco; and Dr. Ramanath Bhandari from Springfield Clinic Eye Institute, will provide their perspectives on the treatment landscape, unmet needs, and the commercial readiness of sura-vec in wet AMD.

REGENXBIO, which has been at the forefront of AAV gene therapy since its founding in 2009, continues to advance a pipeline of one-time treatments for rare and retinal diseases. The company's late-stage pipeline includes RGX-202 for the treatment of Duchenne, clemidsogene lanparvovec (RGX-121) for the treatment of MPS II, and RGX-111 for the treatment of MPS I, all in collaboration with Nippon Shinyaku. Additionally, sura-vec is in partnership with AbbVie for the treatment of wet AMD and diabetic retinopathy.

The event will run from 1:00 p.m. ET to 4:00 p.m. ET and will be accessible both in-person and via webcast. An archived replay of the webcast will be available on REGENXBIO's website for approximately 30 days following the event. For more information, interested parties can register for the webcast at the provided link. REGENXBIO Inc. (Nasdaq: RGNX) is a pioneer in the field of AAV gene therapy, with a mission to improve lives through the curative potential of gene therapy.

Since its founding in 2009, REGENXBIO has been dedicated to advancing innovative treatments for rare and retinal diseases. The company's pipeline includes RGX-202 for the treatment of Duchenne, clemidsogene lanparvovec (RGX-121) for the treatment of MPS II, and RGX-111 for the treatment of MPS I, all in partnership with Nippon Shinyaku. Sura-vec, in collaboration with AbbVie, is being developed for the treatment of wet AMD and diabetic retinopathy.

The event is designed to provide investors and stakeholders with an in-depth understanding of the sura-vec clinical program and the broader context of gene therapy in the treatment of wet AMD. The perspectives of leading retina specialists will offer valuable insights into the unmet needs in the field and the potential of sura-vec to address these challenges.